γδ TCR--> αβTCR: (Part3)

Part-3: Trans-differentiation of the TCR of CD4+ Vδ1+ γδT-Cell Clones into αβTCR

This part of the series will aim to discuss the detailed developmental steps of the trans-differentiation of CD4+ Vδ1+ γδT-cells to fully functional αβ T cells.

The CD4+ Vδ1+ γδT-cells clones were reportedly extremely long-lived and had a downregulated expression of CD34. In the clones that continued to grow with Vδ1+ γδTCRs, authors tracked the commitment change to αβTCR over one month. At day 7, the initially Vδ1+ γδT-cells that were negative for αβTCR, now started to express an αβTCR and became low on γδTCR. This expression profile changed entirely on day 28, where the cells became αβTCR(+) γδTCR(lo). The CD4 and CD8 expression on these clones was also evaluated and it turned out that the cells remained either SP CD4+ or changed their co-receptor from SP CD4+ --> DP CD4+/CD8dim. This resulted into cell pool containig either SP CD4+ or SP CD8+ αβTCR(+) T cell clones. Original figure (5) from the paper shows more details on staining.

Developmental steps leading to trans-differentiation

Expression of the constant region of TCR chains was used as a focal point whilst evaluating the re-organization of these clones. The chronological steps in which this change occurs is as follows:

  1. CD34 is down-regulated
  2. DN1-stage like Vδ1+ Cγ1+ Vδ1+ γδT-cells express CD4 and undergo morphological changes during proliferation
  3. Cells now become DN2-stage like where they are still αβ negative, but lower in expression of both Vδ1+ and Cγ chains, and start expressing Cβ chain. At this point cells have an LGL like proliferation profile
  4. Expression of the β-chain leads to progression towards DN3-stage and thereby further downregulation of the Vδ1 chain and ablation of Cγ chain replaced by a Cβ chain altogether
  5. Cells undergo β-chain selection with a fully formed Cβ chain, cells undergo DP-like developmental stage, where the expression of CD4+CD8+ αβTCR is dim but the competitive binding of Vβ1+Vδ1 vs. Vβ+Vα+ begins.
  6. At this point, the processive α-chain rearrangement occurs that deletes the δ-chain and leads to positive selection and form a DPb stage and express Ca+Cb+Vd1-Cg-
  7. Finally, the SP TCRαβ+ cells yield CD4+ or CD8+ αβ+TCR cells.

This summary can be shown graphically in the following summary figure extracted from the paper.

2015-05-10 14_49_36-fimmu-05-00645-g012.jpg (992×659).png

I adore this paper. It is not an easy paper to read with many critical and meticulous experimental details, but if you were to gloss over them and just focus on the things I did, you might find:

  • If, under severe inflammatory conditions, a mature Vδ1+ γδ TCR can undergo gene re-organization and form a fully functional CD4+ or CD8+ αβ TCR, that not only changes our convention of T-cell lineage but also build on the existsing perspective of the plasticity of these re-arrangements.

  • As a γδ T cell scientist, I always enjoy a paper that shows ways to expand and functionally characterize the non-conventional T cells in humans. While, some schools of thoughts still categorize γδ T cells as innate like lymphoid cells (ILCs), there are many that consider γδ T cells to be a member of the adaptive arm. Me, on the other hand, would go even a step further and put them in yet another category of "bridging immunity". While, γδ T cells are first to respond at sites of inflammation in many models and are able to expand in recall responses, Ziegler shows that they are also able to trans-differentiate into fully functional αβTCRs.

Further experiments need to be done in different model systems to truly assure that the clonal reorganization of TCR commitments is changing and not just an artifact. Ziegler et al does a fantastic job in their discussion by validating the findings by comparing them to evidences put forth by other papers in the last couple decades.

It would also be interesting to see this sort of a model for gene re-organization in more severe infectious models such as HIV and malignant tumors. One wonders if the tumor microenviroment poses such reorganization and if so, does that make the tumor malignancy more severe?

Please feel free to clarify points that I may have missed or misinterpreted.

γδ TCR--> αβTCR (Part 2)

Built on the foundation of last entry's T cell lineage commitment summary, this part will focus on the specifics of observed characteristics of heterodimeric TCR bearing (γδ/αβ) clones of CD4+ Vδ1+ γδ T cells.

Part-2: Characteristics of CD4+ Vδ1+ γδ T cell clones 

Ziegler and colleagues were able to make extremely long-lived clones of CD4+ Vδ1+ γδ T cell clones by culturing lymphocytes from healthy individuals and observed the following:

  1. Clones were able to change their TCRs from γδ to αβ over time
  2. Clone morphology was similar to that of Large granular lymphocytes (LGLs)
  3. Constant region of the TCR-γ9+ chain contained a Cγ1 region
  4. Clones expressed CD34(lo), CXCR4, TGF-β and receptor, IL-7R, c-Kit and FLT-3.
  5. Like DN1-stage, CD4+ Vδ1+ γδ T cell clones were CD34+ (albeit low) CD38+ CD1a-.
  6. Clones rapidly expressed CD2 during cultivation, which was initially absent
  7. Spontaneously produced cytokines such as TGF-β, IL-2, -4, -5, -6, -10, -13, -17A, IFN-γ and TNF-α upon PMA+IONO
  8. Clones were CD45RO+, CD45RA-, CDG2L-, CD27- and CCR7-.. and therefore, characterized as effector memory cells.

Let's look at a couple of these in more detail.

(3) is interesting where they found that the C-region of TCR-γ9+ chain employs a Cγ1 region.

There are two major subpopulations of γδ T cells based on their "V" and "C" gene segment usage. In the PBMCs, majority of γδ TCRs are Vγ9/Vδ2. TCR of these chains link the γ and the δ chains via di-sulfide linkages. Therefore, the TCRγ and chains use the Cγ1 region and not Cγ2. Salvatore Ciccarese and colleagues wrote this beautiful paper comparing the differences in Cγ regions by the γδTCRs in three species: humans, mice and artiodactyls. Study is titled, "Evolution of T-cell Receptor Gamma and Delta Constant Region and Other T-Cell-Related Proteins in the Human-Rodent-Artiodactyl Triplet." In humans, he says, the main differences between the Cγ1 and Cγ2 is simple: there are 3 exons for Cγ1 and four for Cγ2. The second exon is duplicated in the Cγ2 which lacks a Cysteine that makes a di-sulfide bridge, and hence, Cγ1 is a major segment used by the TCRγ9 chains.

(8) Clones were likely effector memory cells. This is by far the most interesting characteristic because these clones are extremely long lived and are isolated from healthy human PBMCs. Ziegler et al states that these are not naiive but are effector memory cells. The reason this is the case is because they did not express the CD45RA Ag, suggesting they are not naive. To clarify, CD45RA is expressed on naïve T cells, as well as the effector cells in CD4+ populations. However, upon Ag experience, central (Tcm) and effector (Tem) memory T cells gain expression of CD45RO and lose expression of CD45RA. Therefore, we use either CD45RA or CD45RO to generally differentiate the naïve from memory populations. Another way to further differentiate naiive from effector or central memory is by quantitating the expression of CCR7 or CD62L. While both naiive and central memory cells expresss CCR7 and CD62L, effector memory or effector cells tend not to.

CD4+ Vδ1+ γδ T cell clones expressed CD45RO+, but not CD45RA, CD62L, CD27, or CCR7− and sometimes expressed CD28. While they lacked the CCR7 expression, the clones expressed other chemokine receptors such as CCR4, CXCR1/CXCR2, CCR6, and CXCR4 - which direct the movement of circulating T cells to sites of inflammation and tissue injury. This is important detail to remember and ties back the inflammatory microenvironment of the ex vivo cultures. Ziegler et al shows that the CD4+ Vδ1+ γδT cells

that lack thymus-homing properties but carry chemokine receptors (CCR) that direct circulating T cells to sites of inflammation, can develop into functional, mature CD4+ or CD8+ αβT cells in an inflammatory environment.

Individual steps of this development will be discussed in part 3.